Servier, 50 rue Carnot - 92284 Suresnes, France.
Future Oncol. 2019 Jul;15(19):2191-2197. doi: 10.2217/fon-2019-0125. Epub 2019 May 31.
. Dr Claude Bertrand graduated in pharmacy (PharmD) from Strasbourg University, France, and obtained his PhD in Strasbourg with research in the fields of immunopharmacology and neurogenic inflammation. After a 2-year postdoctoral appointment at the University of California, San Francisco, USA, Claude joined the allergy and asthma unit at Ciba-Geigy (later Novartis) in Basel, Switzerland. In 1996, he moved to the Inflammatory Disease Unit at Roche Bioscience, CA, USA, where he became the head of the pharmacology group and was responsible for supporting projects in rheumatology and respiratory diseases. In 1999, he was recruited as Director of Biology for Inflammation, GI and Pain at Parke-Davies, which later became part of Pfizer where he headed drug discovery. In 2004, Dr Bertrand joined AstraZeneca as Vice President of Discovery for Respiratory and Inflammation Research at Alderley Park, UK, and, in 2005, he was appointed Global Senior Vice President for Respiratory and Inflammation Research Area overseeing research and development activities at three sites in the UK and Sweden. In 2009, Dr Bertrand joined Ipsen, France, as Executive Vice President, Chief Scientific Officer, and from June 2011 was the Executive Vice President for Research and Development, Chief Scientific Officer with a focus on oncology, neurology and endocrinology. In March 2017, he was appointed General Director R&D, Chief Scientific Officer at Servier and has recently been promoted to Executive Vice President R&D. As such, he joined the Executive Committee on 1 November 2018. Claude sits on the Board of Directors of Eclosion2 and ABIVAX, and is also part of the Scientific Advisory Board of MEDALIS. He was the President of ARIIS from 2011 to 2016. Since 2014, he has been on the Board of Hcéres. Claude has published more than 70 papers in peer-reviewed journals, authored 20 chapters and presented more than 100 communications at scientific meetings. Since 1996, he has been a visiting lecturer for PhD student programs at universities in London, Strasbourg, Nancy, Rennes, Orléans and Paris.
克劳德·贝特朗博士毕业于法国斯特拉斯堡大学，获得药学博士学位，并在斯特拉斯堡从事免疫药理学和神经原性炎症领域的研究。在美国加州大学旧金山分校完成为期两年的博士后研究后，克劳德加入瑞士巴塞尔的 Ciba-Geigy（后来的诺华）过敏和哮喘科。1996 年，他转至罗氏生物科学炎症疾病科，担任药理学小组组长，并负责支持风湿和呼吸疾病项目。1999 年，他被聘为辉瑞旗下 Parke-Davies 炎症、胃肠道和疼痛生物学部主任，负责领导药物发现工作。2004 年，贝特朗博士加入阿斯利康，担任英国奥尔德利公园呼吸和炎症研究部副总裁，2005 年，他被任命为呼吸和炎症研究全球高级副总裁，负责监督英国和瑞典三个基地的研发活动。2009 年，他加入法国益普生公司，担任执行副总裁、首席科学官，自 2011 年 6 月起担任研发执行副总裁、首席科学官，专注于肿瘤学、神经病学和内分泌学。2017 年 3 月，他被任命为 Servier 研发部总经理、首席科学官，最近晋升为研发执行副总裁。因此，他于 2018 年 11 月 1 日加入执行委员会。克劳德是 Eclosion2 和 ABIVAX 的董事会成员，也是 MEDALIS 科学顾问委员会的成员。他曾于 2011 年至 2016 年担任 ARIIS 主席。自 2014 年以来，他一直担任 Hcéres 董事会成员。克劳德在同行评议期刊上发表了 70 多篇论文，撰写了 20 章章节，并在科学会议上发表了 100 多次交流。自 1996 年以来，他一直担任伦敦、斯特拉斯堡、南希、雷恩、奥尔良和巴黎大学博士生项目的客座讲师。
